Cue Biopharma, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Key Points:

• The 2026 Annual Meeting of Cue Biopharma, Inc. was held on April 13, 2026.
• Shareholders voted on four major proposals, all of which were approved.
• One proposal included the approval of a reverse stock split, which is highly price-sensitive.

Details of Matters Voted Upon:

1. Election of Directors

Shareholders elected the nominees to Cue Biopharma’s Board of Directors. The elected directors will serve until the next annual meeting, resignation, removal, or until their successors are duly elected and qualified. The exact votes for each director are not detailed, but the election was certified and successful.

2. Ratification of Independent Auditor

Shareholders ratified the appointment of RSM US LLP as Cue Biopharma’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This ratification received strong support with 10,847,178 votes in favor and 502,071 votes against.

3. Advisory Vote on Executive Compensation

A non-binding advisory proposal on the compensation of named executive officers was approved by shareholders. This “Say on Pay” vote is an important signal of shareholder support for the Company’s management and compensation practices. The proposal received 24,931,610 votes in favor.

4. Approval of Reverse Stock Split

This is the most price-sensitive item for shareholders:

• Shareholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of Cue Biopharma’s common stock.
• The reverse split ratio is set within a range of not less than 1-for-30 and not more than 1-for-50.
• The exact ratio and timing are to be determined at the sole discretion of Cue Biopharma’s Board of Directors, without further shareholder approval.

This reverse stock split is potentially significant for share price and shareholder value. Reverse splits are often implemented to meet minimum price requirements for continued listing on stock exchanges, or to bolster perceived value, but can also signal financial distress. Investors should monitor subsequent announcements from the Company regarding the specific ratio and timing of the reverse split, as it could have a material impact on share liquidity and valuation.

Other Information

• Cue Biopharma remains listed on the Nasdaq Capital Market under trading symbol CUE.
• The company is not classified as an “emerging growth company,” which could affect the applicability of certain regulatory exemptions.
• No proposals regarding written communications, soliciting material, or pre-commencement tender offers were indicated as being relevant to this filing.

Shareholder Considerations:

• The reverse stock split approval is a key price-sensitive event, as it directly affects the number of shares outstanding and the per-share price.
• Shareholders should be aware that the Board has broad discretion to implement the split at any time and at any ratio within the approved range.
• This could impact trading volumes and the attractiveness of the stock to institutional investors.
• Ratification of the auditor and approval of executive compensation are generally viewed as routine, but the strong support for these items may indicate confidence in management and governance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with their financial advisors before making any investment decisions. The article is based on publicly available SEC filings and may not reflect all developments affecting Cue Biopharma, Inc. Shareholders should monitor Company press releases and regulatory filings for further updates.

View Cue Biopharma, Inc. Historical chart here